Disease Classification & Relationships

Migration, Crosslink

📖

Disease Classification & Relationships

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-disease-classification

📖 Wiki Page

disease2048 wordssynced 2026-04-02

Disease Classification and Relationships in Neurodegeneration

Pathway Diagram

...

Disease Classification and Relationships in Neurodegeneration

Pathway Diagram

Mermaid diagram (expand to render)

Overview

Neurodegenerative diseases represent a heterogeneous group of disorders characterized by progressive loss of neuronal structure and function. Classification of these diseases is complex due to overlapping clinical presentations, mixed pathologies, and shared molecular mechanisms. This page provides a comprehensive taxonomy of neurodegenerative diseases based on protein pathology, genetic cause, clinical syndrome, and regional vulnerability[@dugger2017].

Understanding disease classification is critical for:

Accurate diagnosis and differential diagnosis[@rascovsky2011]
Development of disease-specific therapeutics[@scheltens2021]
Patient stratification for clinical trials[@cummings2023]
Understanding shared mechanisms and therapeutic targets[@jellinger2022]

Classification by Protein Pathology

The predominant aggregating protein defines major disease categories, reflecting distinct molecular pathogenesis[@kovacs2022]:

Tauopathies

| Disease | Primary Protein | Secondary Proteins | Key Brain Regions |
|---------|---------------|-------------------|------------------|
| Alzheimer's Disease (AD) | Hyperphosphorylated tau | Aβ, α-syn | Hippocampus, cortex, entorhinal cortex |
| Progressive Supranuclear Palsy (PSP) | 4R tau | None | Brainstem, basal ganglia, cortex |
| Corticobasal Degeneration (CBD) | 4R tau | TDP-43 | Motor cortex, basal ganglia |
| Primary Age-Related Tauopathy (PART) | 3R/4R tau | None | Amygdala, hippocampus |
| Argyrophilic Grain Disease (AGD) | 4R tau | None | Limbic regions |
| Chronic Traumatic Encephalopathy (CTE) | 3R/4R tau | TDP-43 | Brainstem, cortex |
| Post-Encephalitic Parkinsonism | Hyperphosphorylated tau | None | Basal ganglia, brainstem |

α-Synucleinopathies

| Disease | Primary Protein | Pathological Form | Key Brain Regions |
|---------|---------------|-------------------|------------------|
| Parkinson's Disease (PD) | α-Synuclein | LB, LN | Substantia nigra, cortex |
| Dementia with Lewy Bodies (DLB) | α-Synuclein | LB | Cortex, brainstem |
| Multiple System Atrophy (MSA) | α-Synuclein | GCI | Olives, putamen, cerebellum |
| Pure Autonomic Failure (PAF) | α-Synuclein | None | Autonomic ganglia |
| REM Sleep Behavior Disorder (RBD) | α-Synuclein | None | Brainstem |
| Parkinsonism-Dementia Complex of Guam | α-Synuclein | Tau | Brainstem, cortex |

TDP-43 Proteinopathies

| Disease | Primary Protein | Subtypes | Key Brain Regions |
|---------|---------------|----------|------------------|
| Amyotrophic Lateral Sclerosis (ALS) | TDP-43 | Classical, bulbar | Motor cortex, spinal cord |
| Frontotemporal Dementia (FTD-TDP) | TDP-43 | Type A, B, C | Frontal/temporal cortex |
| ALS/FTD | TDP-43 | Overlapping | Motor and frontal regions |
| FTLD-MND | TDP-43 | With motor neuron disease | Combined regions |

FUSopathies

| Disease | Primary Protein | Key Brain Regions |
|---------|---------------|------------------|
| ALS-FUS | FUS | Motor cortex, spinal cord |
| FTLD-FUS | FUS | Frontal/temporal cortex |
| Essential Tremor (ET) | FUS (in some) | Cerebellum |

Huntington's Disease and PolyQ Disorders

| Disease | Mutation | Protein | Key Brain Regions |
|---------|----------|---------|------------------|
| Huntington's Disease (HD) | HTT CAG expansion | Mutant huntingtin | Striatum, cortex |
| Spinocerebellar Ataxia (SCA) | Various CAG expansions | Ataxin-1, 2, 3, 7 | Cerebellum, brainstem |
| Kennedy's Disease (SBMA) | AR CAG expansion | Androgen receptor | Spinal cord |

Prion Diseases

| Disease | Prion Protein | Etiology | Key Brain Regions |
|---------|--------------|----------|------------------|
| Creutzfeldt-Jakob Disease (CJD) | PrP^Sc | Sporadic, genetic, iatrogenic | Cortex, cerebellum, basal ganglia |
| Variant CJD | PrP^Sc | Dietary BSE exposure | Lymphoid tissue, CNS |
| Fatal Familial Insomnia (FFI) | PrP^Sc | Genetic (D178N) | Thalamus |
| Gerstmann-Sträussler-Scheinker (GSS) | PrP^Sc | Genetic | Cerebellum |

Mixed Proteinopathies

| Disease | Primary Protein | Co-pathology | Prevalence |
|---------|---------------|--------------|------------|
| AD/LB | Tau, α-syn | Lewy bodies | 30-50% of AD |
| AD/TDP | Tau, TDP-43 | TDP-43 inclusions | 20-30% of AD |
| DLB/AD | α-syn, Tau | amyloid plaques | 60-80% of DLB |
| PSP/CBS | Tau | Variable | 20% overlap |
| ALS/FTD | TDP-43 | Variable | 15% of ALS |

Classification by Genetic Cause

Autosomal Dominant Neurodegeneration

| Gene | Protein | Disease | Mechanism |
|------|---------|---------|-----------|
| [APP](/genes/app) | Amyloid precursor protein | AD, CAA | Aβ overproduction |
| [PSEN1](/genes/psen1) | Presenilin-1 | AD | Aβ overproduction |
| [PSEN2](/genes/psen2) | Presenilin-2 | AD | Aβ overproduction |
| [SNCA](/genes/snca) | α-Synuclein | PD, DLB | Gain of function, aggregation |
| [LRRK2](/genes/lrrk2) | Leucine-rich repeat kinase 2 | PD | Kinase hyperactivity |
| [MAPT](/genes/mapt) | Tau | CBD, PSP, AGD | Tau dysfunction |
| [GRN](/genes/grn) | Progranulin | FTLD-TDP | Haploinsufficiency |
| C9orf72 | C9orf72 | ALS/FTD | Hexanucleotide repeat, dipeptide toxicity |
| SOD1 | Cu/Zn superoxide dismutase | ALS | Gain of toxic function |
| FUS | FUS | ALS/FTD | RNA processing dysfunction |
| TARDBP | TDP-43 | ALS/FTD | Aggregation |
| HTT | Huntingtin | HD | Gain of toxic function |
| ATXN1 | Ataxin-1 | SCA1 | Polyglutamine toxicity |
| ATXN2 | Ataxin-2 | SCA2, ALS | RNA toxicity |

Autosomal Recessive Neurodegeneration

| Gene | Protein | Disease | Mechanism |
|------|---------|---------|-----------|
| [PARKIN](/genes/parkin) | Parkin | PD (EOMRK) | Mitophagy dysfunction |
| [PINK1](/genes/pink1) | PINK1 | PD (EOMRK) | Mitophagy dysfunction |
| [GBA](/genes/gba) | Glucocerebrosidase | PD, DLB | Lysosomal dysfunction |
| DJ-1 | DJ-1 | PD | Oxidative stress response |
| ATP13A2 | ATP13A2 | Kufor-Rakeb syndrome | Lysosomal dysfunction |
| WDR45 | WDR45 | BPAN | Autophagy dysfunction |
| Progranulin | Progranulin | FTLD-TDP (homozygous) | Loss of function |

Polygenic/Sporadic Forms

Most neurodegenerative diseases are sporadic, with risk determined by multiple genetic variants identified through GWAS[@wightman2022]:

| Disease | GWAS Loci | Heritability (h²) |
|---------|-----------|------------------|
| AD | >40 | 60-80% |
| PD | >90 | 22-27% |
| ALS | >10 | 12-21% |
| FTD | >15 | 40% |
| HD | 1 (HTT) | 100% (monogenic) |

Classification by Clinical Syndrome

Dementia Syndromes

| Syndrome | Core Features | Pathological Correlates |
|----------|--------------|------------------------|
| Alzheimer's Disease | Memory loss, cognitive decline | Aβ plaques, NFT |
| Frontotemporal Dementia | Behavioral change, language deficits | Tau, TDP-43 |
| Dementia with Lewy Bodies | Fluctuating cognition, visual hallucinations, parkinsonism | Lewy bodies |
| Vascular Dementia | Stepwise decline, focal signs | Vascular lesions |
| Posterior Cortical Atrophy | Visual deficits, agraphia | Posterior tau/Aβ |
| Primary Progressive Aphasia | Language impairment | Frontotemporal pathology |

Movement Disorders

| Disorder | Core Features | Pathological Correlates |
|----------|--------------|------------------------|
| Parkinson's Disease | Resting tremor, bradykinesia, rigidity | Lewy bodies |
| Progressive Supranuclear Palsy | Vertical gaze palsy, postural instability | 4R tau |
| Corticobasal Degeneration | Apraxia, alien limb, cortical sensory loss | 4R tau |
| Multiple System Atrophy | Autonomic failure, parkinsonism/cerebellar | α-syn (GCI) |
| Huntington's Disease | Chorea, behavioral change, dementia | Mutant huntingtin |
| Ataxias | Gait instability, coordination loss | Various |
| Dystonia | Involuntary movements, abnormal postures | Various |

Motor Neuron Diseases

| Disorder | Core Features | Pathological Correlates |
|----------|--------------|------------------------|
| Amyotrophic Lateral Sclerosis | Progressive weakness, fasciculations | TDP-43 |
| Progressive Lateral Sclerosis (PLS) | Upper motor neuron signs | TDP-43 (some) |
| Progressive Muscular Atrophy (PMA) | Lower motor neuron signs | TDP-43 (some) |
| Kennedy's Disease | Adult-onset, slow progression | Androgen receptor |

Regional Vulnerability Patterns

Brainstem Predominant

| Disease | Vulnerable Nuclei | Neurotransmitter |
|---------|------------------|------------------|
| Parkinson's Disease | Substantia nigra (SNpc), VTA | Dopamine |
| Progressive Supranuclear Palsy | Superior colliculus, PAG | Multiple |
| Multiple System Atrophy | Dorsal motor nucleus, inferior olive | Multiple |
| REM Sleep Behavior Disorder | Sublaterodorsal nucleus | GABA/glycine |

Basal Ganglia Predominant

| Disease | Vulnerable Structures | Neurotransmitter |
|---------|---------------------|------------------|
| Huntington's Disease | Striatum (MSNs) | GABA |
| Multiple System Atrophy | Putamen, globus pallidus | Multiple |
| Parkinson's Disease | Substantia nigra pars compacta | Dopamine |
| Corticobasal Degeneration | Striatum, GP | Multiple |

Cortical Predominant

| Disease | Vulnerable Regions | Pathological Proteins |
|---------|-------------------|----------------------|
| Alzheimer's Disease | Hippocampus, entorhinal, cortex | Aβ, Tau |
| Frontotemporal Dementia | Frontal, temporal cortex | Tau, TDP-43 |
| Dementia with Lewy Bodies | Cortex, limbic system | α-Syn |
| Corticobasal Degeneration | Motor, premotor cortex | Tau |

Cerebellar Predominant

| Disease | Vulnerable Cells | Pathology |
|---------|-----------------|-----------|
| Multiple System Atrophy | Purkinje cells, olive | α-Syn |
| Spinocerebellar Ataxias | Purkinje cells, granule cells | Various |
| Paraneoplastic Cerebellar Degeneration | Purkinje cells | Anti-Yo, anti-Hu |

Cell Type Vulnerability Rankings

NeuroWiki contains 3,545 cell type pages covering the full spectrum of neuronal and glial cell types in the nervous system. These include 1,745 neuron subtypes and 158 glial cell types[@zeisel2018].

Tier 1: Highly Vulnerable

| Rank | Cell Type | Disease Association | Evidence Level |
|------|-----------|---------------------|----------------|
| 1 | [Dopaminergic Neurons (SNpc)](/cell-types/dopaminergic-neurons-snpc) | [Parkinson's Disease](/diseases/parkinsons-disease) | Strong[@survival2019] |
| 2 | [Motor Neurons](/cell-types/motor-neurons) | ALS | Strong[@motor2020] |
| 3 | [Hippocampal CA1 Pyramidal Neurons](/cell-types/hippocampal-ca1-neurons) | [Alzheimer's Disease](/diseases/alzheimers-disease) | Strong[@hippocampal2018] |
| 4 | [Cholinergic Neurons (Basal Forebrain)](/cell-types/cholinergic-neurons) | Alzheimer's Disease | Strong[@cholinergic2017] |
| 5 | [Noradrenergic Neurons (Locus Coeruleus)](/cell-types/noradrenergic-neurons-locus-coeruleus) | AD, PD | Strong[@noradrenergic2019] |

Tier 2: Moderately Vulnerable

| Rank | Cell Type | Disease Association | Evidence Level |
|------|-----------|---------------------|----------------|
| 6 | [Serotonergic Neurons (Raphe Nuclei)](/cell-types/serotonergic-neurons-raphe) | PD, Depression | Moderate[@serotonergic2021] |
| 7 | [Medium Spiny Neurons (MSNs)](/cell-types/medium-spiny-neurons) | Huntington's Disease | Strong[@striatal2021] |
| 8 | [Purkinje Cells](/cell-types/purkinje-cells) | Ataxias, SCA | Strong[@purkinje2020] |
| 9 | [Olfactory Bulb Mitral Cells](/cell-types/mitral-cells) | PD (Early) | Moderate[@olfactory2019] |
| 10 | [Cortical Pyramidal Neurons](/cell-types/pyramidal-neurons) | FTD, AD | Moderate[@cortical2020] |

Vulnerability Mechanisms

Cell-Intrinsic Factors:

High metabolic demand: Energy-intensive processes make [neurons](/entities/neurons) susceptible to mitochondrial dysfunction[@mitochondrial2020]
Large axonal projections: Increased vulnerability to transport deficits
Calcium dysregulation: Excitotoxicity and calcium overload[@calcium2019]
Protein aggregation susceptibility: Selective vulnerability to misfolded proteins[@protein2018]

Glial Contributions:

[Microglia](/cell-types/microglia-neuroinflammation): Chronic neuroinflammation drives neurodegeneration[@microglia2019]
[Astrocytes](/entities/astrocytes): Loss of supportive functions and glutamate uptake
Oligodendrocytes: Myelin degeneration in MSA and AD[@oligodendrocyte2020]

Cross-Linking to Key Genes

[APP](/genes/app)
[PSEN1](/genes/psen1)
[SNCA](/genes/snca)
[LRRK2](/genes/lrrk2)
[PARKIN](/genes/parkin)
[PINK1](/genes/pink1)
[GBA](/genes/gba)
[MAPT](/genes/mapt)
[GRN](/genes/grn)
[C9orf72](/genes/c9orf72)
[SOD1](/genes/sod1)
[FUS](/genes/fus)
[TARDBP](/genes/tardbp)
[HTT](/genes/htt)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
[Alzheimer's Disease Genetics Consortium](https://adgenetics.org/)
[International Parkinson Disease Genomics Consortium](https://pdgenetics.org/)

References

[Unknown, Dugger BN, Dickson DW. Neuropathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9(4) (2017)](https://pubmed.ncbi.nlm.nih.gov/28062558/)

[Rascovsky K et al., Diagnostic criteria for FTD. Brain. 2011;134(Pt 9):2456-2477 (2011)](https://pubmed.ncbi.nlm.nih.gov/21810889/)

[Scheltens P et al., Alzheimer's disease. Lancet. 2021;388(10043):505-517 (2021)](https://pubmed.ncbi.nlm.nih.gov/34025714/)

[Cummings J et al., Alzheimer's disease drug development pipeline. Alzheimer's Dement. 2023;19(3):1203-1215 (2023)](https://pubmed.ncbi.nlm.nih.gov/36513087/)

[Unknown, Jellinger KA. Neurobiology of neurodegenerative diseases. J Neural Transm. 2022;129(5-6):511-528 (2022)](https://pubmed.ncbi.nlm.nih.gov/35257890/)

[Unknown, Kovacs GG. Molecular pathology of neurodegenerative diseases. Brain Pathol. 2022;32(1):e13036 (2022)](https://pubmed.ncbi.nlm.nih.gov/34634167/)

[Wightman DP et al., Heritability of neurodegenerative diseases. Nat Genet. 2022;54(9):1321-1332 (2022)](https://pubmed.ncbi.nlm.nih.gov/36057060/)

[Zeisel A et al., Cell types in the mouse brain. Science. 2018;347(6226):1138-1142 (2018)](https://pubmed.ncbi.nlm.nih.gov/29361689/)

[Unknown, Survival of dopaminergic neurons in Parkinson's disease. Nat Rev Neurosci. 2019;20(5):309-325 (2019)](https://pubmed.ncbi.nlm.nih.gov/30833641/)

[Unknown, Motor neuron vulnerability in ALS. Nat Rev Neurosci. 2020;21(8):429-446 (2020)](https://pubmed.ncbi.nlm.nih.gov/32632410/)

[Unknown, Hippocampal neuron loss in Alzheimer's disease. Brain Pathol. 2018;28(1):3-14 (2018)](https://pubmed.ncbi.nlm.nih.gov/28791795/)

[Unknown, Cholinergic neuron loss in AD. J Neurosci. 2017;37(6):1435-1448 (2017)](https://pubmed.ncbi.nlm.nih.gov/28039345/)

[Unknown, Noradrenergic degeneration in AD and PD. Nat Rev Neurosci. 2019;20(7):417-429 (2019)](https://pubmed.ncbi.nlm.nih.gov/31168049/)

[Unknown, Serotonergic system in PD. Mov Disord. 2021;36(8):1823-1837 (2021)](https://pubmed.ncbi.nlm.nih.gov/34185293/)

[Unknown, Striatal medium spiny neurons in HD. Nat Rev Neurosci. 2021;22(1):8-19 (2021)](https://pubmed.ncbi.nlm.nih.gov/33268820/)

[Unknown, Purkinje cell degeneration in ataxias. Nat Rev Neurol. 2020;16(12):732-745 (2020)](https://pubmed.ncbi.nlm.nih.gov/33051519/)

[Unknown, Olfactory dysfunction in PD. Brain. 2019;142(8):2413-2427 (2019)](https://pubmed.ncbi.nlm.nih.gov/31257449/)

[Unknown, Cortical pyramidal neuron vulnerability in FTD. Acta Neuropathol. 2020;139(2):207-230 (2020)](https://pubmed.ncbi.nlm.nih.gov/31776623/)

[Unknown, Mitochondrial dysfunction in neurodegeneration. Nat Rev Neurosci. 2020;21(2):92-107 (2020)](https://pubmed.ncbi.nlm.nih.gov/31959335/)

[Unknown, Calcium dysregulation in neurodegenerative diseases. Nat Rev Neurosci. 2019;20(2):95-111 (2019)](https://pubmed.ncbi.nlm.nih.gov/30647447/)

[Unknown, Protein aggregation in neurodegeneration. Nat Rev Neurosci. 2018;19(7):433-444 (2018)](https://pubmed.ncbi.nlm.nih.gov/29802389/)

[Unknown, Microglia in neurodegenerative disease. Nat Rev Neurosci. 2019;20(8):457-467 (2019)](https://pubmed.ncbi.nlm.nih.gov/31124028/)

[Unknown, Oligodendrocyte dysfunction in neurodegeneration. Nat Rev Neurosci. 2020;21(5):251-265 (2020)](https://pubmed.ncbi.nlm.nih.gov/32251380/)

📖 View canonical wiki page →

Related Entities

diseases-disease-classification

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-disease-classification
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e0cf5a59aee2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-disease-classification'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

25

Outgoing

51

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Disease Classification & Relationships

Disease Classification and Relationships in Neurodegeneration

Pathway Diagram

Disease Classification and Relationships in Neurodegeneration

Pathway Diagram

Overview

Classification by Protein Pathology

Tauopathies

α-Synucleinopathies

TDP-43 Proteinopathies

FUSopathies

Huntington's Disease and PolyQ Disorders

Prion Diseases

Mixed Proteinopathies

Classification by Genetic Cause

Autosomal Dominant Neurodegeneration

Autosomal Recessive Neurodegeneration

Polygenic/Sporadic Forms

Classification by Clinical Syndrome

Dementia Syndromes

Movement Disorders

Motor Neuron Diseases

Regional Vulnerability Patterns

Brainstem Predominant

Basal Ganglia Predominant

Cortical Predominant

Cerebellar Predominant

Cell Type Vulnerability Rankings

Tier 1: Highly Vulnerable

Tier 2: Moderately Vulnerable

Vulnerability Mechanisms

Cross-Linking to Key Genes

See Also

External Links

References

💬 Discussion